title: Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
abstract: Plerixafor, a recently approved peripheral blood progenitor cell mobilizing agent, is often added to granulocyte-colony stimulating factor (G-CSF) to mobilize peripheral blood progenitor cells in patients with lymphoma or myeloma who cannot mobilize enough CD34+ cells with G-CSF alone to undergo autologous stem cell transplantation. However, data are lacking regarding the feasibility and efficacy of just-in-time plerixafor in combination with chemotherapy and G-CSF. We reviewed the peripheral blood stem cell collection data of 38 consecutive patients with lymphoma (Hodgkin's and non-Hodgkin's) and multiple myeloma who underwent chemomobilization and high-dose G-CSF and just-in-time plerixafor to evaluate the efficacy of this treatment combination. All patients with multiple myeloma and all but one patient with lymphoma collected the minimum required number of CD34+ cells to proceed with autologous stem cell transplantation (>2 × 10(6) /kg of body weight). The median CD34+ cell dose collected in patients with non-Hodgkin lymphoma was 4.93 × 10(6) /kg of body weight. The median CD34+ cell dose collected for patients with multiple myeloma was 8.81 × 10(6) /kg of body weight. Plerixafor was well tolerated; no grade 2 or higher non-hematologic toxic effects were observed.
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Veronica R
authors.initials: VR
authors.lastname: Smith
authors.forename: Uday
authors.initials: U
authors.lastname: Popat
authors.forename: Stefan
authors.initials: S
authors.lastname: Ciurea
authors.forename: Yago
authors.initials: Y
authors.lastname: Nieto
authors.forename: Paolo
authors.initials: P
authors.lastname: Anderlini
authors.forename: Gabriela
authors.initials: G
authors.lastname: Rondon
authors.forename: Amin
authors.initials: A
authors.lastname: Alousi
authors.forename: Muzaffar
authors.initials: M
authors.lastname: Qazilbash
authors.forename: Partow
authors.initials: P
authors.lastname: Kebriaei
authors.forename: Issa
authors.initials: I
authors.lastname: Khouri
authors.forename: Marcos
authors.initials: M
authors.lastname: de Lima
authors.forename: Richard
authors.initials: R
authors.lastname: Champlin
authors.forename: Chitra
authors.initials: C
authors.lastname: Hosing
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000276:immunology; D001596:Benzylamines; D002452:Cell Count; D000080027:Cyclams; D004359:Drug Therapy, Combination; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation; D006571:Heterocyclic Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor